Salivary Gland Cancer Clinical Trials

Doctors at Memorial Sloan Kettering are constantly working to improve treatment for salivary gland cancer through research studies called clinical trials. Participating in a clinical trial may give you access to treatments that are not widely available elsewhere. A clinical trial may offer you additional options if your cancer has returned after standard treatment.

For salivary gland cancers, our doctors are running clinical trials testing in these areas:

  • new drug therapies to boost the effectiveness of care
  • safer and more-effective approaches to radiation therapy
  • strategies for preserving the quality of life during and after treatment

For people with advanced disease, we offer a genomic test called MSK-IMPACT™. The test, developed by MSK experts, currently screens for more than 450 genetic mutations linked to cancer, and we continue to identify more.

Based on which mutations we find in your tumor, we may be able to offer you a clinical trial testing a drug designed to work against those mutations.

Our experts can help determine which clinical trials are right for you. Browse our listing of clinical trials that are currently enrolling new patients.

and/or
6 Clinical Trials found
A Phase 1 Study of PYX-201 in People With Advanced Solid Tumors
Researchers are evaluating PYX-201 in people with solid tumors that have spread and keep growing after treatment. The people in this study have these cancers:
New York City, Commack, Basking Ridge, Westchester, Monmouth, Bergen, Nassau
A Phase 1 Study of REM-422 in People With Adenoid Cystic Cancer
Researchers want to find the best dose of REM-422 to use in people with advanced adenoid cystic cancer (ACC). ACC most commonly starts in the salivary glands. The people in this study have ACC that has spread and may high levels of a protein called MYB. This protein can cause cancer cells to grow.
New York City, Commack, Basking Ridge, Westchester, Monmouth, Bergen, Nassau
A Phase 1 Study of RGT-61159 in People With Adenoid Cystic Carcinoma
In this study, researchers want to find the best dose of RGT-61159 to treat salivary gland cancer. The people in this study have adenoid cystic carcinoma that came back or keeps growing after treatment.
New York City, Commack, Basking Ridge, Westchester, Monmouth, Bergen, Nassau
A Phase 2 Study of Ado-Trastuzumab Emtansine in People With Salivary Gland Cancer
Researchers are assessing ado-trastuzumab emtansine (T-DM1) to treat salivary gland cancer. The people in this study have cancer that is operable (can be removed with surgery) and makes a protein called HER2. T-DM1 targets cancer cells that make HER2. In this study, it will be combined with radiation therapy and chemotherapy after the tumor has been removed by surgery.
New York City, Commack, Basking Ridge, Westchester, Monmouth, Bergen, Nassau
A Phase 2 Study of Enfortumab Vedotin in People With Adenoid Cystic Carcinoma
Researchers want to see how well enfortumab vedotin works in people with adenoid cystic carcinoma. This cancer most often starts in the salivary glands and certain other glands in the body. The people in this study have adenoid cystic cancer that came back or spread after treatment.
New York City, Commack, Basking Ridge, Westchester, Monmouth, Bergen, Nassau
A Phase II Study of Ado-Trastuzumab Emtansine Compared to the Usual Treatment for Advanced HER2-Positive Salivary Gland Cancer
In this study, researchers are comparing ado-trastuzumab emtansine with the usual treatment (docetaxel and trastuzumab) in people with recurrent, inoperable, or metastatic salivary gland cancer that makes the HER2 protein. Ado-trastuzumab emtansine is a monoclonal antibody (trastuzumab) linked to a chemotherapy drug (emtansine). Trastuzumab attaches to HER2 on cancer cells and delivers emtansine to kill them.
New York City, Commack, Basking Ridge, Westchester, Monmouth, Bergen, Nassau